Translating co-stimulation blockade into clinical practice.

about

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.The efficacy and safety of abatacept in rheumatoid arthritis.Why can't we find a new treatment for SLE?Emerging drugs for psoriatic arthritis.

P2860

Q30399745-64517DD1-7425-4F81-8F39-9038B0E50056 Q36059373-0747C544-AFAF-44A5-ABDF-1D9F322E4306 Q37236049-F0351FB6-FDA9-48F3-BE60-2154628423E0 Q37763192-7AB829A9-616E-4722-91F2-F29F158DFA54

P2860

Translating co-stimulation blockade into clinical practice.

Item

http://www.wikidata.org/entity/Q36972500

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Translating co-stimulation blockade into clinical practice.

@en

type

Item

label

Translating co-stimulation blockade into clinical practice.

@en

prefLabel

Translating co-stimulation blockade into clinical practice.

@en

P1476

Translating co-stimulation blockade into clinical practice

@en

P2093

Rene Westhovens

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.

Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis.

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases

P2888

ar2415

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR2415

http://www.w3.org/2001/XMLSchema#string

P478

10 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Verschueren

P577

2008-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23471810

http://www.w3.org/2001/XMLSchema#string

P698

19007424

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

globulins

blood proteins

P932

2582811

http://www.w3.org/2001/XMLSchema#string

Translating co-stimulation blockade into clinical practice.

about

P2860

P2860

Translating co-stimulation blockade into clinical practice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932